Literature DB >> 16097847

Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.

Howard Schubiner1.   

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a common disorder in children that frequently persists into adulthood. Studies have found that substance use disorders (SUD) are seen more commonly in those with ADHD than the general population. Although treatment with stimulant medications has been shown to be effective for individuals with ADHD, concern about the use of these agents in this population persists. This review article highlights the research in this area with a focus on the treatment of individuals who present with concomitant ADHD and SUD. Although stimulants can be abused, studies have shown that adolescents who are prescribed stimulants for ADHD have lower rates of SUD than those who are not treated with stimulants. It may be particularly difficult to evaluate adults for the diagnosis of ADHD when SUD is a co-morbid factor. Studies show that 20--30% of adults presenting with SUD have concomitant ADHD and approximately 20--40% of adults with ADHD have histories of SUD. Therefore, it is critical to perform careful diagnostic interviews to discern if patients have either or both of these disorders. Many clinical experts suggest that adults with ADHD and active SUD be treated for the SUD until a period of sobriety persists prior to initiation of specific treatment for ADHD. Since individuals with ADHD and active SUD are more likely to have more severe SUD and a worse prognosis, this approach may not serve many patients, as they relapse prior to obtaining ADHD treatment. Therefore, research has been directed towards determining if the treatment of ADHD with stimulant medications can be safe and effective for the individual with active SUD and concomitant ADHD. An initial trial of methylphenidate in a population of adults with active cocaine dependence and ADHD indicates that this is the case. Individuals with ADHD and SUD can present difficult diagnostic and therapeutic challenges. It appears that the most effective treatment option is to create a programme that uses the most effective treatment modalities available, including both behavioural and medical therapies, along with close supervision and monitoring. Newer medical treatment options of long-acting stimulants and non-stimulants (e.g. atomoxetine) offer effective treatment with a lower risk of abuse potential.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16097847     DOI: 10.2165/00023210-200519080-00001

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  87 in total

1.  Practical guidelines for the treatment of substance abusers with adult attention-deficit hyperactivity disorder.

Authors:  F R Levin; S M Evans; H D Kleber
Journal:  Psychiatr Serv       Date:  1999-08       Impact factor: 3.084

2.  Attention deficit hyperactivity disorder: a worldwide concern.

Authors:  Joseph Biederman; Stephen V Faraone
Journal:  J Nerv Ment Dis       Date:  2004-07       Impact factor: 2.254

Review 3.  Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders.

Authors:  J Biederman; J Newcorn; S Sprich
Journal:  Am J Psychiatry       Date:  1991-05       Impact factor: 18.112

4.  Assessment of symptoms of attention-deficit hyperactivity disorder in adults with substance use disorders.

Authors:  R Milin; E Loh; J Chow; A Wilson
Journal:  Psychiatr Serv       Date:  1997-11       Impact factor: 3.084

Review 5.  Attention-deficit/hyperactivity disorder in adults: an overview.

Authors:  S V Faraone; J Biederman; T Spencer; T Wilens; L J Seidman; E Mick; A E Doyle
Journal:  Biol Psychiatry       Date:  2000-07-01       Impact factor: 13.382

6.  Trends in the prescribing of psychotropic medications to preschoolers.

Authors:  J M Zito; D J Safer; S dosReis; J F Gardner; M Boles; F Lynch
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

7.  Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence?

Authors:  J Biederman; T E Wilens; E Mick; S V Faraone; T Spencer
Journal:  Biol Psychiatry       Date:  1998-08-15       Impact factor: 13.382

8.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Authors:  David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382

9.  Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study.

Authors:  F R Levin; S M Evans; D M McDowell; H D Kleber
Journal:  J Clin Psychiatry       Date:  1998-06       Impact factor: 4.384

10.  Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain.

Authors:  N D Volkow; Y S Ding; J S Fowler; G J Wang; J Logan; J S Gatley; S Dewey; C Ashby; J Liebermann; R Hitzemann
Journal:  Arch Gen Psychiatry       Date:  1995-06
View more
  16 in total

1.  New developments in the treatment of attention-deficit/hyperactivity disorder in primary care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

2.  Comparison of the Adult ADHD Self Report Scale Screener for DSM-IV and DSM-5 in a Dually Diagnosed Correctional Population.

Authors:  Leo Bastiaens; James Galus
Journal:  Psychiatr Q       Date:  2018-06

Review 3.  Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.

Authors:  Yu-Shu Huang; Ming-Horng Tsai
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

4.  A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder.

Authors:  Aimee L McRae-Clark; Rickey E Carter; Therese K Killeen; Matthew J Carpenter; Kathleen G White; Kathleen T Brady
Journal:  Am J Addict       Date:  2010-09-21

Review 5.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

6.  Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician.

Authors:  Himanshu P Upadhyaya
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

7.  Widespread cortical thinning is a robust anatomical marker for attention-deficit/hyperactivity disorder.

Authors:  Katherine L Narr; Roger P Woods; James Lin; John Kim; Owen R Phillips; Melissa Del'Homme; Rochelle Caplan; Arthur W Toga; James T McCracken; Jennifer G Levitt
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-10       Impact factor: 8.829

8.  Reinforcing effects of methamphetamine in an animal model of attention-deficit/hyperactivity disorder--the spontaneously hypertensive rat.

Authors:  Ike dela Peña; Hyung Seok Ahn; Ji Young Choi; Chan Young Shin; Jong Hoon Ryu; Jae Hoon Cheong
Journal:  Behav Brain Funct       Date:  2010-12-09       Impact factor: 3.759

Review 9.  The influence of sex-linked genetic mechanisms on attention and impulsivity.

Authors:  Simon Trent; William Davies
Journal:  Biol Psychol       Date:  2011-10-06       Impact factor: 3.251

Review 10.  Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence.

Authors:  Kenneth M Dürsteler; Eva-Maria Berger; Johannes Strasser; Carlo Caflisch; Jochen Mutschler; Marcus Herdener; Marc Vogel
Journal:  Subst Abuse Rehabil       Date:  2015-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.